Myocardial energetics and ubiquinol in diastolic heart failure

Diastolic heart failure, or heart failure with preserved ejection fraction, is a leading cause of morbidity and mortality. There are no current therapies effective in improving outcomes for these patients. The aim of this article is to review the literature and examine the role of coenzyme Q10 in he...

Full description

Saved in:
Bibliographic Details
Published in:Nursing & health sciences 2014-12, Vol.16 (4), p.428-433
Main Authors: Bates, Angelina, Shen, Qiuhua, Hiebert, John B., Thimmesch, Amanda, Pierce, Janet D.
Format: Article
Language:English
Subjects:
Antioxidants
ATP
coronary artery disease
Dietary supplements
Drug therapy
heart disease
Heart failure
Heart Failure, Diastolic - drug therapy
Heart Failure, Diastolic - metabolism
Heart Failure, Diastolic - physiopathology
HFpEF
Humans
Hypertension - physiopathology
Mortality
myocardial energetics
Nursing
ubiquinol
Ubiquinone - analogs & derivatives
Ubiquinone - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diastolic heart failure, or heart failure with preserved ejection fraction, is a leading cause of morbidity and mortality. There are no current therapies effective in improving outcomes for these patients. The aim of this article is to review the literature and examine the role of coenzyme Q10 in heart failure with preserved ejection fraction related to mitochondrial synthesis of adenosine triphosphate and reactive oxygen species production. The study results reflect that myocardial energetics alters in diastolic heart failure and that there is defective energy metabolism and increased oxidative stress. Studies are emerging to evaluate coenzyme Q10, particularly ubiquinol, as a supplemental treatment for heart‐failure patients. In diastolic heart‐failure patients, clinicians are beginning to use supplemental therapies to improve patient outcomes, and one promising complementary treatment to improve left ventricular diastolic function is ubiquinol. Additional studies are needed using large‐scale randomized models to confirm if ubiquinol would be beneficial. Since ubiquinol is an antioxidant and is required for adenosine triphosphate production, clinicians and health scientists should be aware of the potential role of this supplement in the treatment of diastolic heart failure.
ISSN:1441-0745
1442-2018
DOI:10.1111/nhs.12168